Hualan Biological: Jointly invested company receives drug registration clinical trial acceptance notification.

On December 16th, Hualan Biotechnology announced that its joint venture company Hualan Genetic Engineering Co., Ltd. has received the "Acceptance Notice" for the application of domestic production drug registration clinical trial of pembrolizumab injection issued by the National Medical Products Administration. The drug is called pembrolizumab injection, with the application for domestic production drug registration clinical trial, registered under the category of therapeutic biologics class 3.3, specification of 100mg/bottle. The indications for the drug include melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, etc.